AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

New insights into what causes the painful and disruptive symptoms of urinary tract infections (UTIs) could offer hope for improved treatment. UTIs are one of the most prevalent bacterial infections ...

A new study from the University of Minnesota and Mayo Clinic has found that people who are hospitalized for infections face a ...

According to the CDC, nearly three million people in the U.S. get antibiotic resistant infections every year, and around ...

A recent study conducted on human A(H5N1) cases in the United States found that conjunctivitis was the primary symptom ...

Researchers have developed nanoflower-coated bandages with antibiotic and anti-inflammatory properties, capable of killing ...